Michael Artinger, PhD

Michael Artinger, PhD
Michael Artinger, PhD, Executive Vice President and Managing Director VIC Colorado Branch, has spent his career transforming innovation into commercial opportunity. He has worked closely with universities and inventors across the nation to recognize the potential of their discoveries and has deep domain expertise across multiple verticals, including therapeutics, vaccines, medical devices, diagnostics and information technology/software. Dr. Artinger earned his Doctorate degree in Biology focusing on Developmental and Cell Biology, as well as his Baccalaureate degree in Applied Ecology from the University of California at Irvine.
Find me on:

Recent Posts

Maximizing Synergies Between Venture Studios and Life Science Companies

As has been thoroughly discussed by this author and others, the so-called “valley of death” is a critical barrier for the advancement of life science (therapeutic, vaccine, medical device, diagnostic and related)...

Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia

Aurora, CO - Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR)...

Part 3: Challenges and Solutions for University Technology Commercialization – Gap Programs

Both universities and regional entities have become more active in providing critically needed support to faculty innovators with commercially relevant technologies.

Solaris Vaccines Awarded Funding from NIH to Develop Novel Influenza Vaccine using SolaVAX™ Platform

This NIAID SBIR will evaluate an innovative approach for producing superior vaccines more quickly and cost-effectively. FORT COLLINS, CO – Solaris Vaccines, Inc. announced today that it has received a Small Business...

Direct-to-Phase II SBIR Grant from NIH Awarded to Neurexis Therapeutics to Evaluate Neuroprotective Therapeutic in Stroke Preclinical Assessment Network (SPAN)

A promising approach for preventing cognitive and behavioral impairment following ischemia Aurora, CO - Neurexis Therapeutics, Incorporated, announces it has been awarded $900,000 in funding from a Direct-to-Phase II...

Solaris Vaccines Adds Izabela Ragan as Director of Research and Development for the SolaVAX™ Platform

FORT COLLINS, CO – Solaris Vaccines, Inc. announced today that Dr. Izabela Ragan (DVM, PhD), an expert in novel vaccine technologies, has joined as Director of Research and Development. The Company is developing a...

From the Corner Office: Michael Artinger, PhD – CEO of Solaris Vaccines, Inc.

I have been very fortunate to have had a varied and diverse career accelerating the development of life science innovation, including therapeutics, vaccines, medical devices, diagnostics, analytical instruments,...

Part 2: Challenges and Solutions for University Technology Commercialization - License Terms

In Part 1 of this series, I touched on some of the unique considerations for advancing early-stage innovation beyond the academic setting. For this article, I’d like to dig deeper into the topic of university...

Part 1: Challenges and Solutions for University Technology Commercialization

The honest truth? Deciding which early-stage technologies will be successful is really hard. This is even more the case when you add the challenges faced in a university setting. Although I’m currently on the investment...

From the Corner Office: Neurexis Therapeutics

Let me start by saying that the last two years have been a case study on focusing on priorities and filtering out noise. I’m fortunate to work in an area where it’s easy to see the long-term value of what we...

FEATURED RESOURCES

Updates
VIC Tech Announces New Class of Fellows
Insight
Our Life Science and Healthcare Future
White Paper
Portfolio Diversification in Times of Market Volatility
Interview
Inside the Office of Technology Commercialization at the University of Kentucky with Holly Clark, PhD, Senior Commercialization Manager
Insight
Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio
White Paper
Investing in Medical Devices & Diagnostics – Industry Trends and Investor Activity
News
Nob Hill Therapeutics Secures Series A Funding to Advance Breakthrough Respiratory Technologies
Interview
VIC Fellows Spotlight: Matthew Leming, PhD
From The Corner Office
From the Corner Office: Zebra Analytix